High-Dose Corticosteroid Administration Induces Increase of Serum Macrophage Migration Inhibitory Factor in Patients with Vogt-Koyanagi-Harada's Disease

• Published in: MICROBIOLOGY and IMMUNOLOGY Vol. 44; no. 12; pp. 1075 - 1077
• Main Authors: Kitaichi, Nobuyoshi, Kotake, Satoshi, Mizue, Yuka, Sasamoto, Yoichi, Goda, Chiho, Iwabuchi, Kazuya, Onoé, Kazunori, Matsuda, Hidehiko, Nishihira, Jun
• Format: Journal Article
• Language: English
• Published: Tokyo Blackwell Publishing Ltd 01.01.2000; Center For Academic Publications Japan; Center for Academic Publications Japan
• Subjects: Administration, Oral; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - therapeutic use; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Corticosteroid; Dose-Response Relationship, Drug; Glucocorticoids - administration & dosage; Glucocorticoids - therapeutic use; Humans; Injections, Intravenous; Macrophage Migration-Inhibitory Factors - blood; Medical sciences; migration inhibitory factor; Pharmacology. Drug treatments; Prednisolone - administration & dosage; Prednisolone - therapeutic use; Serum MIF; TNF-α; Tumor Necrosis Factor-alpha - analysis; Uveomeningoencephalitic Syndrome - blood; Uveomeningoencephalitic Syndrome - drug therapy; VKH disease; Vogt-Koyanagi-Harada's disease; Human; Corticosteroid; Skin disease; Nervous system diseases; Pigmentation disorder; Cytokine; Antiinflammatory agent; Uvea disease; Inflammation; Immunity; Dose activity relation; Macrophage migration inhibitory factor; Eye disease; Chemotherapy; Treatment; Vogt Koyanagi uveitis; Central nervous system disease; Meningitis; Tumor necrosis factor α
• ISSN: 0385-5600; 1348-0421
• DOI: 10.1111/j.1348-0421.2000.tb02606.x

To investigate the influence of corticosteroid administration on the serum level of macrophage migration inhibitory factor (MIF), sera obtained from 9 patients with Vogt-Koyanagi-Harada's disease who had been treated with high-dose corticosteroid were analyzed. The serum MIF levels of most patients were prominently increased on day 7 and/or day 14 after corticosteroid treatment. No TNF-α was detected in the sera. The average serum MIF level of nine patients at the highest stages after corticosteroid administration was significantly higher than that before the corticosteroid treatment. It seems that MIF is a unique cytokine and acts together with corticosteroid to regulate inflammation and immunity.